Avinger Inc (AVGR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avinger Inc (AVGR) has a cash flow conversion efficiency ratio of -0.738x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.86 Million) by net assets ($3.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Avinger Inc net asset quality index to measure how much of total assets are equity-financed.
Avinger Inc - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how Avinger Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore AVGR cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Avinger Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avinger Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biosergen AS
ST:BIOSGN
|
-0.954x |
|
Labrador Technologies Inc
V:LTX
|
0.099x |
|
Bone Biologics Corp
NASDAQ:BBLG
|
-0.133x |
|
BlackRock Latin American Investment Trust plc
LSE:BRLA
|
0.074x |
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
0.350x |
|
GeoVax Labs Inc
NASDAQ:GOVX
|
-1.266x |
|
INVO Fertility, Inc.
NASDAQ:IVF
|
-0.304x |
|
INCUVO S.A. ZY -50
F:68X
|
0.135x |
Annual Cash Flow Conversion Efficiency for Avinger Inc (2012–2023)
The table below shows the annual cash flow conversion efficiency of Avinger Inc from 2012 to 2023. For the full company profile with market capitalisation and key ratios, see AVGR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-6.20 Million | $-14.43 Million | 2.327x | +157.56% |
| 2022-12-31 | $4.15 Million | $-16.76 Million | -4.042x | -150.40% |
| 2021-12-31 | $9.72 Million | $-15.70 Million | -1.614x | -42.30% |
| 2020-12-31 | $13.08 Million | $-14.84 Million | -1.135x | +54.69% |
| 2019-12-31 | $6.89 Million | $-17.26 Million | -2.504x | -28.27% |
| 2018-12-31 | $9.46 Million | $-18.47 Million | -1.952x | -302.07% |
| 2017-12-31 | $-35.69 Million | $-34.48 Million | 0.966x | +107.72% |
| 2016-12-31 | $4.24 Million | $-53.07 Million | -12.513x | -377.14% |
| 2015-12-31 | $15.59 Million | $-40.88 Million | -2.623x | -1830.66% |
| 2014-12-31 | $-143.87 Million | $-21.80 Million | 0.152x | -57.96% |
| 2013-12-31 | $-112.78 Million | $-40.66 Million | 0.360x | -24.66% |
| 2012-12-31 | $-73.64 Million | $-35.23 Million | 0.478x | -- |
About Avinger Inc
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to prov… Read more